Literature DB >> 14968483

Is there a continuum of psychotic experiences in the general population?

Jim van Os1.   

Abstract

AIMS: Schizophrenia is a severe mental illness that affects 1% of the population. The diagnosis is made according to current diagnostic systems of DSM-IV (American Psychiatric Association, 1994) and ICD-10 (World Health Organisation, 1992), on the basis of characteristic 'positive' and 'negative' symptoms. The traditional model assumes a categorical view of the schizophrenia syndrome and its core symptoms, in which differences between psychotic symptoms and their normal counterparts are considered to be qualitative. An alternative, dimensional approach assumes that schizophrenia is not a discrete illness entity, but that psychotic symptoms differ in quantitative ways from normal experiences and behaviours. This paper reviews evidence for the continuity of psychotic symptoms with normal experiences, focusing on the symptoms of hallucinations and delusions.
METHODS: A qualitative review of the relevant literature.
RESULTS: The literature suggests that although current epidemiological approaches yield substantial evidence for a continuum view, it is rarely interpreted as such.
CONCLUSIONS: The traditional concept of schizophrenia as a homogeneous disease entity has become outdated and is in dire need of a more valid and clinically useful successor.

Entities:  

Mesh:

Year:  2003        PMID: 14968483     DOI: 10.1017/s1121189x00003067

Source DB:  PubMed          Journal:  Epidemiol Psichiatr Soc        ISSN: 1121-189X


  24 in total

1.  Family Aided Community Treatment for the Treatment of Early Psychosis: A Proof of Concept Study.

Authors:  Ryan P Melton; Cass Dykeman
Journal:  Community Ment Health J       Date:  2016-01-06

Review 2.  [Deconstructing schizophrenia. Dimensional models or division into subtypes?].

Authors:  M Jäger; K Frasch; F U Lang; T Becker
Journal:  Nervenarzt       Date:  2012-03       Impact factor: 1.214

Review 3.  [The crisis of the operational diagnostic approach in psychiatry].

Authors:  M Jäger; K Frasch; T Becker
Journal:  Nervenarzt       Date:  2008-03       Impact factor: 1.214

Review 4.  Schizophrenia, "Just the Facts" 6. Moving ahead with the schizophrenia concept: from the elephant to the mouse.

Authors:  Matcheri S Keshavan; Henry A Nasrallah; Rajiv Tandon
Journal:  Schizophr Res       Date:  2011-02-12       Impact factor: 4.939

Review 5.  Hallucinations in the general population.

Authors:  Louise C Johns
Journal:  Curr Psychiatry Rep       Date:  2005-06       Impact factor: 5.285

6.  Auditory hallucinations in a cross-diagnostic sample of psychotic disorder patients: a descriptive, cross-sectional study.

Authors:  Ann K Shinn; Danielle Pfaff; Sarah Young; Kathryn E Lewandowski; Bruce M Cohen; Dost Öngür
Journal:  Compr Psychiatry       Date:  2011-12-22       Impact factor: 3.735

7.  The psychosis continuum in the general population: findings from the São Paulo Epidemiologic Catchment Area Study.

Authors:  Alexandre Andrade Loch; Yuan-Pang Wang; Wulf Rössler; Luis Fernando Tófoli; Camila Magalhães Silveira; Laura Helena Andrade
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-16       Impact factor: 5.270

8.  Varieties of Voice-Hearing: Psychics and the Psychosis Continuum.

Authors:  Albert R Powers; Megan S Kelley; Philip R Corlett
Journal:  Schizophr Bull       Date:  2016-10-07       Impact factor: 9.306

9.  Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos.

Authors:  Paolo Cassano; Trina Chang; Nhi-Ha Trinh; Lee Baer; Maurizio Fava; David Mischoulon
Journal:  J Affect Disord       Date:  2013-03-13       Impact factor: 4.839

10.  Psychotic-like experiences in major depression and anxiety disorders: a population-based survey in young adults.

Authors:  Daniel Varghese; James Scott; Joy Welham; William Bor; Jake Najman; Michael O'Callaghan; Gail Williams; John McGrath
Journal:  Schizophr Bull       Date:  2009-08-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.